Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Standard Lithium Ltd — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B), while Standard Lithium Ltd trades at $1.61 (market cap $398.07M). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 63.5× Standard Lithium Ltd's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Standard Lithium Ltd for 23 Days on average.
| RPRX | SLI | |
|---|---|---|
Market Cap | $25.27B | $398.07M |
Volume | 3,671,183 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $63.96 | $5.65 |
52-Week Low | $35.44 | $1.61 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $32.50B | $260.98M |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE of -15.55% and ROA of -14.17%, though recent quarterly EPS beat expectations. Positive developments include progress toward a 2026 final investment decision for the Arkansas lithium project and expanded offtake agreements. Cash flow remains supported by financing activities despite negative operational cash flow.
The investment case hinges on successful project execution and lithium market dynamics. Analysts are unanimously bullish with a $3.83 price target, representing significant upside. Key risks include execution delays, negative cash flow, and commodity price volatility. The stock offers high-risk, high-reward exposure to North American lithium production growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
